[Diagnostic use of the GRF test in the study of GH secretion].
Ramos. M M; Fernández. A A; Ferrández. A A; Mayayo. E E; Guallar. A A
Key Findings
- An IV bolus of GRF‑1‑29 produces a clear GH response in patients whose deficiency is due to lack of hypothalamic GRF.
- Non‑responders may require pulsatile or prolonged GRF administration and concurrent T4 replacement if they also have TSH deficiency.
- Absence of any GH response to GRF suggests a pure pituitary GH deficiency, which is best treated with direct GH therapy.
Practical Outcomes
- For biohackers interested in using GRF, the study highlights that a single dose is mainly a diagnostic tool, not a performance enhancer. If you suspect a hypothalamic issue, consider a longer‑acting or pulsed GRF protocol and check thyroid status. Pure pituitary deficiencies will not benefit from GRF and need direct GH supplementation.
Summary
Giving a single IV dose of the peptide GRF‑1‑29 can help doctors figure out whether a person’s growth‑hormone problem comes from the brain (hypothalamus) or the pituitary gland. Some people who seem to have a hypothalamic issue don’t react to a one‑time dose, so they may need a longer or pulsed GRF regimen and thyroid hormone support. If there’s no reaction at all, the problem is likely in the pituitary and direct growth‑hormone therapy is needed.
Abstract
A good response after an intravenous bolus of GRF-1-29 NH2 in patients with hypopituitary dwarfism localities the site of the GH-deficiency in the hypothalamus (GRF deficiency). These patients could be treated with GH and GRF. Never the less some patients with hypothalamic responses after TRH don't respond after GRF. Probably these non responders need GRF in pulsatile or prolonged administration and T4 substitution before and during the test if TSH is also deficient. At least some cases without GRF response can be accepted as pure pituitary only GH would be effective.
Study Information
pubmed
1987